Back - to - back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone - related genetic abnormality can help predict individual patient responses to
specific prostate cancer therapies.
Not exact matches
The findings inject hard facts into a debate that has long divided the medical community, with many radiation oncologists preferring adjuvant
therapy — radiation given soon after
prostate removal to kill off any remaining
cancer cells — and many urologists preferring salvage
therapy — radiation given later, when
prostate -
specific antigen tests suggest it's needed.
The researchers, at The Institute of
Cancer Research, London, and The Royal Marsden NHS Foundation Trust, say their test is the first developed for a precision prostate cancer therapy targeted at specific genetic faults within tu
Cancer Research, London, and The Royal Marsden NHS Foundation Trust, say their test is the first developed for a precision
prostate cancer therapy targeted at specific genetic faults within tu
cancer therapy targeted at
specific genetic faults within tumours.
All had been treated previously with at least one type of androgen deprivation
therapy and had rising levels of
prostate specific antigen (PSA), a blood marker for
prostate cancer, and radiographic evidence their
cancers were becoming resistant.
Targeted Alpha
Therapy of
prostate cancer uses PSMA - 617, an anti-PSMA (Prostate Specific Membrane Antigen) peptide that specifically binds to prostate cancer cells, but not to normal, health
prostate cancer uses PSMA - 617, an anti-PSMA (
Prostate Specific Membrane Antigen) peptide that specifically binds to prostate cancer cells, but not to normal, health
Prostate Specific Membrane Antigen) peptide that specifically binds to
prostate cancer cells, but not to normal, health
prostate cancer cells, but not to normal, healthy cells.